Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04305613 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Cardiotoxicity in Locally Advanced Lung Cancer Patients Treated With Chemoradiation Therapy

Study acronym: CLARITY
StatusActive, Not Recruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 2 months later Sep 2026 → Dec 2026
See other at-risk trials from Abramson Cancer Center at Penn Medicine

Record History

  1. Primary completion pushed from Sep 2026 to Dec 2026 Eligibility criteria expanded, about 9 words · Secondary endpoints: details revised at 5 of 16 entries · Site details revised at 2 of 8 sites Show 3 more changesShow less
    • Eligibility criteria expanded, about 9 words
    • Secondary endpoints: details revised at 5 of 16 entries
    • Site details revised at 2 of 8 sites
  2. Primary completion date: Aug 2025 to Sep 2026 Trial status: Enrolling by Invitation to Active, Not Recruitingv16 Show 1 more changeShow less
    • Trial status: Enrolling by Invitation to Active, Not Recruiting
  3. Primary completion date: Dec 2025 to Aug 2025 Completion date: Dec 2028 to Dec 2030v15 Show 1 more changeShow less
    • Completion date: Dec 2028 to Dec 2030
  4. Study Identification, Study Status, Oversightv14
  5. Study sites: 7 to 8v13
Show 11 earlier versionsHide 11 earlier versions
  1. Primary completion date: Sep 2025 to Dec 2025 Completion date: Sep 2028 to Dec 2028v12 Show 1 more changeShow less
    • Completion date: Sep 2028 to Dec 2028
  2. Eligibility criteria shortened, about 5 wordsv11 See this version in full on ClinicalTrials.gov ↗
  3. Study sites: 5 to 7v10
  4. Study sites: 3 to 5v9
  5. Study sites: 2 to 3v8
  6. Re-verified, no change to tracked fieldsv7
  7. Trial status: Not Yet Recruiting to Enrolling by Invitation Primary completion date: Aug 2025 to Sep 2025 · Completion date: Aug 2028 to Sep 2028 · Start date changed from estimate of Aug 26, 2020 to Sep 14, 2020 · 1 morev6 Show 4 more changesShow less
    • Primary completion date: Aug 2025 to Sep 2025
    • Completion date: Aug 2028 to Sep 2028
    • Start date changed from estimate of Aug 26, 2020 to Sep 14, 2020
    • Site contacts updated at 1 of 2 sites
  8. Primary completion date: Jul 2025 to Aug 2025 Completion date: Jul 2028 to Aug 2028 · Start date: Jul 2020 to Aug 26, 2020v5 Show 2 more changesShow less
    • Completion date: Jul 2028 to Aug 2028
    • Start date: Jul 2020 to Aug 26, 2020
  9. Study sites: 1 to 2v4
  10. Primary completion date: Jun 2025 to Jul 2025 Completion date: Jun 2028 to Jul 2028 · Start date: Jun 2020 to Jul 2020v3 Show 2 more changesShow less
    • Completion date: Jun 2028 to Jul 2028
    • Start date: Jun 2020 to Jul 2020
  11. Start date: Apr 2020 to Jun 2020 Primary completion date: Apr 2025 to Jun 2025 · Completion date: Apr 2028 to Jun 2028 · Secondary endpoints: details revised at 3 of 16 entries · 1 morev2 Show 4 more changesShow less
    • Primary completion date: Apr 2025 to Jun 2025
    • Completion date: Apr 2028 to Jun 2028
    • Secondary endpoints: details revised at 3 of 16 entries
    • Study description expanded, about 3 words

    See this version in full on ClinicalTrials.gov ↗

  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This observational cohort will evaluate the cardiovascular effects of chemoradiation used to treat locally advanced, non-small cell lung cancer. Patients will be enrolled prior to the start of therapy and followed during and for at least 2 years after therapy with echocardiograms, nuclear stress tests, blood sampling, and quality of life surveys.
Trial Details
NCT Number NCT04305613
Lead Sponsor Abramson Cancer Center at Penn Medicine
Conditions Cardiotoxicity, Lung Cancer Stage III, Lung Cancer Stage II, Radiation Toxicity
Enrollment 221 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov